Talaris Therapeutics Statistics Share Statistics Talaris Therapeutics has 42.81M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 42.81M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 4.21M Failed to Deliver (FTD) Shares 12,694 FTD / Avg. Volume 8.88%
Short Selling Information The latest short interest is 211.84K, so 0% of the outstanding
shares have been sold short.
Short Interest 211.84K Short % of Shares Out n/a Short % of Float 1% Short Ratio (days to cover) 1.09
Valuation Ratios The PE ratio is -0.94 and the forward
PE ratio is null.
Talaris Therapeutics's PEG ratio is
0.
PE Ratio -0.94 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.23 P/FCF Ratio -0.89 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Talaris Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 30.18,
with a Debt / Equity ratio of 0.
Current Ratio 30.18 Quick Ratio 30.18 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-871.55K Employee Count 84 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 2.18, so Talaris Therapeutics's
price volatility has been higher than the market average.
Beta 2.18 52-Week Price Change n/a 50-Day Moving Average 2.83 200-Day Moving Average 2.41 Relative Strength Index (RSI) 46.62 Average Volume (20 Days) 142,922
Income Statement
Revenue n/a Gross Profit n/a Operating Income -89.73M Net Income -73.21M EBITDA -89.73M EBIT n/a Earnings Per Share (EPS) -2.89
Full Income Statement Balance Sheet The company has 30.51M in cash and 244K in
debt, giving a net cash position of 30.26M.
Cash & Cash Equivalents 30.51M Total Debt 244K Net Cash 30.26M Retained Earnings -135.26M Total Assets 287.5M Working Capital 250.52M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -77.26M
and capital expenditures -9K, giving a free cash flow of -77.27M.
Operating Cash Flow -77.26M Capital Expenditures -9K Free Cash Flow -77.27M FCF Per Share -3.05
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields TALS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for TALS.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Oct 20, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date Oct 20, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score 8.16 Piotroski F-Score 2
